Inactivating mutations of TRAF2 are frequently detected in human MCL and DLBCL, resulting in elevated activation of NF-κB1 and NF-κB2 in malignant B cells (99–102). The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.